References
- Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et
al. Tisagenlecleucel in Children and Young Adults with B-Cell
Lymphoblastic Leukemia. N Engl J Med . 2018;378(5):439-448.
doi:10.1056/NEJMoa1709866
- Gardner RA, Finney O, Annesley C, Brakke H, Summers C, Leger K, et al.
Intent-to-treat leukemia remission by CD19 CAR T cells of defined
formulation and dose in children and young adults. Blood .
2017;129(25):3322-3331. doi:10.1182/blood-2017-02-769208
- Pasquini MC, Hu ZH, Curran K, Laetsch T, Locke F, Rouce R, et al.
Real-world evidence of tisagenlecleucel for pediatric acute
lymphoblastic leukemia and non-Hodgkin lymphoma [published
correction appears in Blood Adv. 2021 Feb 23;5(4):1136] [published
correction appears in Blood Adv. 2022 Mar 22;6(6):1731]. Blood
Adv . 2020;4(21):5414-5424. doi:10.1182/bloodadvances.2020003092
- Rives S, Maude SL, Hiramatsu, H, Baruchel A, Bader P, Bittencourt H,
et al. S112: Tisagenlecleucel in Pediatric and Young Adult Patients
(Pts) with Relapsed/Refractory (R/R) B-cell Acute Lymphoblastic
Leukemia (B-ALL): Final Analyses from the ELIANA Study.HemaSphere . 2022;6:13-14.
- Grupp SA, Maude SL, Rives S, Baruchel A, Boyer M, Bittencourt H, et
al. Updated Analysis of the Efficacy and Safety of Tisagenlecleucel in
Pediatric and Young Adult Patients with Relapsed/Refractory (r/r)
Acute Lymphoblastic Leukemia. Blood 2018; 132 (Supplement 1):
895. doi:10.1182/blood-2018-99-112599
- Maude SL, Teachey DT, Rheingold SR, Shaw PA, Aplenc R, Barrett DM, et
al. Sustained remissions with CD19-specific chimeric antigen receptor
(CAR)-modified T cells in children with relapsed/refractory ALL.J Clin Oncol . 2016;34(Supplement 15): 3011.
- Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al.
Chimeric antigen receptor T cells for sustained remissions in leukemia
[published correction appears in N Engl J Med. 2016 Mar
10;374(10):998]. N Engl J Med . 2014;371(16):1507-1517.
doi:10.1056/NEJMoa1407222
- Park JH, Rivière I, Gonen M, Wang X, Sénéchal B, Curran KJ, et al.
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic
Leukemia. N Engl J Med . 2018;378(5):449-459.
doi:10.1056/NEJMoa1709919
- Myers RM, Li Y, Barz Leahy A, Barrett DM, Teachey DT, Callahan C, et
al. Humanized CD19-Targeted Chimeric Antigen Receptor (CAR) T Cells in
CAR-Naive and CAR-Exposed Children and Young Adults with Relapsed or
Refractory Acute Lymphoblastic Leukemia. J Clin Oncol .
2021;39(27):3044-3055. doi:10.1200/JCO.20.03458
- Shah NN, Lee DW, Yates B, Yuan C, Shalabi H, Martin S, et al.
Long-Term Follow-Up of CD19-CAR T-Cell Therapy in Children and Young
Adults With B-ALL. J Clin Oncol . 2021;39(15):1650-1659.
doi:10.1200/JCO.20.02262
- Zhang X, Lu XA, Yang J, Zhang G, Li J, Song L, et al. Efficacy and
safety of anti-CD19 CAR T-cell therapy in 110 patients with B-cell
acute lymphoblastic leukemia with high-risk features. Blood
Adv . 2020;4(10):2325-2338. doi:10.1182/bloodadvances.2020001466
- Schultz LM, Baggott C, Prabhu S, Pacenta HL, Phillips CL, Rossoff J,
et al. Disease Burden Affects Outcomes in Pediatric and Young Adult
B-Cell Lymphoblastic Leukemia After Commercial Tisagenlecleucel: A
Pediatric Real-World Chimeric Antigen Receptor Consortium
Report. J Clin Oncol . 2022;40(9):945-955.
doi:10.1200/JCO.20.03585
- Laetsch TW, Maude SL, Balduzzi A, Rives S, Bittencourt H, Boyer MW, et
al. Tisagenlecleucel in pediatric and young adult patients with Down
syndrome-associated relapsed/refractory acute lymphoblastic
leukemia. Leukemia . 2022;36(6):1508-1515.
doi:10.1038/s41375-022-01550-z
- Laetsch TW, Maude SL, Grupp SA, Boyer MW, Harris AC, Qayed M, et al.
CTL019 Therapy Appears Safe and Effective in Pediatric Patients with
Down Syndrome with Relapsed/ Refractory (r/r) Acute Lymphoblastic
Leukemia. Blood 2017; 130 (Supplement 1): 1280.
doi:10.1182/blood.V130.Suppl_1.1280.1280
- Pulsipher MA, Han X, Maude SL, Laetsch TW, Qayed M, Rives S, et al.
Next-Generation Sequencing of Minimal Residual Disease for Predicting
Relapse after Tisagenlecleucel in Children and Young Adults with Acute
Lymphoblastic Leukemia. Blood Cancer Discov . 2022;3(1):66-81.
doi:10.1158/2643-3230.BCD-21-0095
- Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et
al. ASTCT Consensus Grading for Cytokine Release Syndrome and
Neurologic Toxicity Associated with Immune Effector Cells. Biol
Blood Marrow Transplant . 2019;25(4):625-638.
doi:10.1016/j.bbmt.2018.12.758
- Orlando EJ, Han X, Tribouley C, Wood PA, Leary RJ, Riester M, et al.
Genetic mechanisms of target antigen loss in CAR19 therapy of acute
lymphoblastic leukemia. Nat Med . 2018;24(10):1504-1506.
doi:10.1038/s41591-018-0146-z
- Sotillo E, Barrett DM, Black KL, Bagashev A, Oldridge D, Wu G, et al.
Convergence of Acquired Mutations and Alternative Splicing of CD19
Enables Resistance to CART-19 Immunotherapy. Cancer Discov .
2015;5(12):1282-1295. doi:10.1158/2159-8290.CD-15-1020
- Gauthier J, Bezerra ED, Hirayama AV, Fiorenza S, Sheih A, Chou CK, et
al. Factors associated with outcomes after a second CD19-targeted CAR
T-cell infusion for refractory B-cell malignancies. Blood .
2021;137(3):323-335. doi:10.1182/blood.2020006770
- Myers RM, Devine K, Li Y, Lawrence S, Leahy AB, Liu H, et al. Outcomes
after Reinfusion of CD19-Specific Chimeric Antigen Receptor
(CAR)-Modified T Cells in Children and Young Adults with
Relapsed/Refractory B-Cell Acute Lymphoblastic
Leukemia. Blood 2021; 138 (Supplement 1): 474.
doi:10.1182/blood-2021-147299
- Boyer MW, Chaudhury S, Davis KL, Triscoll TA, Grupp SA, Hermiston M,
et al. HESTER: A Phase II Study Evaluating Efficacy and Safety of
Tisagenlecleucel Reinfusion in Pediatric and Young Adult Patients with
Acute Lymphoblastic Leukemia Experiencing Loss of B-Cell
Aplasia. Blood 2020; 136 (Supplement 1): 23–24.
doi:10.1182/blood-2020-136340
- Holland EM, Molina JC, Dede K, Moyer D, Zhou T, Yuan CM, et al.
Efficacy of second CAR-T (CART2) infusion limited by poor CART
expansion and antigen modulation. J Immunother Cancer .
2022;10(5):e004483. doi:10.1136/jitc-2021-004483
- Fabrizio VA, Boelens JJ, Mauguen A, Baggott C, Prabhu S, Egeler E, et
al. Optimal fludarabine lymphodepletion is associated with improved
outcomes after CAR T-cell therapy. Blood Adv .
2022;6(7):1961-1968. doi:10.1182/bloodadvances.2021006418
- Li AM, Hucks GE, Dinofia AM, Seif AE, Teachey DT, Baniewicz D, et al.
Checkpoint Inhibitors Augment CD19-Directed Chimeric Antigen Receptor
(CAR) T Cell Therapy in Relapsed B-Cell Acute Lymphoblastic
Leukemia. Blood 2018; 132 (Supplement 1): 556.
doi:10.1182/blood-2018-99-112572
- Stefanski H, Eaton A, Baggott C, Rossoff J, Verneris MR, Keating AK,
et al. Higher doses of tisagenlecleucel associate with improved
outcomes: a report from the pediatric real-world CAR consortium
[published online ahead of print, 2022 Aug 8]. Blood Adv .
2022;bloodadvances.2022007246. doi:10.1182/bloodadvances.2022007246
- Brentjens RJ, Santos E, Nikhamin Y, Yeh R, Matsushita M, La Perle K,
et al. Genetically targeted T cells eradicate systemic acute
lymphoblastic leukemia xenografts. Clin Cancer Res . 2007;13(18
Pt 1):5426-5435. doi:10.1158/1078-0432.CCR-07-0674